Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2023 HER2+ mBC
SABCS 2023 HER2+ MBC
Phase 3 HER2CLIMB-02 Trial Results of Tucatinib Plus Trastuzumab Emtansine in Previously Treated HER2+ MBC
SABCS 2023 HER2+ MBC
The phase 3 HER2CLIMB-02 trial demonstrated significant prolongation of progression-free survival with tucatinib plus ado-trastuzumab emtansine combination therapy in patients with previously treated HER2+ metastatic breast cancer (MBC).
Read More ›
Correlation of Circulating Tumor Cells with Clinicopathological Factors and Treatment Response in MBC
SABCS 2023 HER2+ MBC
This correlative study identified significant differences in the expression of estrogen receptor between tumor tissue and circulating tumor cell analyses in metastatic breast cancer (MBC).
Read More ›
Characteristics of Exceptional Responders to First-Line HER2-Targeted Therapy for HER2+ MBC
SABCS 2023 HER2+ MBC
In a prospective HER2+ metastatic breast cancer (MBC) cohort, one-third of patients achieved exceptional response to first-line HER2-targeted therapy, who presented more frequently with de novo disease and HER2 immunohistochemistry 3+ tumors.
Read More ›
Updated Overall Survival Analysis of ROSET-BM Trial Shows Trastuzumab Deruxtecan Has Promising Effectiveness in HER2+ MBC
SABCS 2023 HER2+ MBC
Updated overall survival analysis data from a retrospective chart review showed promising efficacy of T-DXd therapy in patients with HER2+ metastatic breast cancer (MBC) with long-term and heavily pretreated brain metastases and/or leptomeningeal carcinomatosis.
Read More ›
Trial in Progress: Phase 3 HER2CLIMB-05 Study of Tucatinib or Placebo Plus Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ MBC
SABCS 2023 HER2+ MBC
The phase 3, randomized, double-blind HER2CLIMB-05 study (NCT05132582) is evaluating the addition of tucatinib to trastuzumab plus pertuzumab as maintenance therapy in patients with HER2+ metastatic breast cancer (MBC).
Read More ›
Quality Improvement Initiative to Develop Individualized Management Strategies for HER2+ MBC
SABCS 2023 HER2+ MBC
Findings of a quality improvement initiative identified several gaps in guideline-aligned patient-centered care in HER2+ metastatic breast cancer (MBC), providing opportunities to implement action plans that improve patient outcomes in the community setting.
Read More ›
Potential Resistance Mechanism to Tucatinib in HER2+ Breast Cancer
SABCS 2023 HER2+ MBC
Hypothesis-generating findings of a retrospective study in a small cohort of tucatinib-treated patients indicates a potential correlation between
KMT2C
mutations and unfavorable clinical outcomes.
Read More ›
Real-world Registry Data for Older Patients with MBC
SABCS 2023 HER2+ MBC
Real-world data from a large, prospective, single-institution cohort of older patients with metastatic breast cancer (MBC) indicated poor survival outcomes with increasing age, particularly for those aged >80 years.
Read More ›
Clinical and Prognostic Differences Between HER2 IHC 2+ and HER2 IHC 3+ Populations in HER2+ MBC
SABCS 2023 HER2+ MBC
Exploratory data indicate that an immunohistochemistry (IHC) score of 3+ is less likely to be associated with lymph node and visceral metastases in patients with HER2+ metastatic breast cancer (MBC), and that site of metastasis has prognostic value in both the IHC 3+ and IHC 2+ subgroups.
Read More ›
Clinical Risk Factors of CNS-Related Death in Patients With HER2+ MBC
SABCS 2023 HER2+ MBC
Results of a single-institution chart review indicated that central nervous system (CNS) involvement directly correlated with CNS-related death in patients with metastatic breast cancer (MBC), with greatest risk in those with leptomeningeal disease.
Read More ›
Page 1 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us